Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL582998

C1CCC(NC2CCCCC2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
HSD17B10 Q99714 1/20 0.55
EPHX1 P07099 5/20 0.44
NPC1 O15118 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
RAB9A P51151 3/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 1/20 0.44
EPHX2 P34913 1/20 0.44
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL973482 0.83 ALDH1A1 (0.71) ALDH1A1HSD17B10EPHX1NPC1SMN1; SMN2
Bicarbonate SCHEMBL11429542 0.83 ALDH1A1 (0.71) ALDH1A1HSD17B10EPHX1NPC1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL3862637 0.83 PDK1 (0.42) ALDH1A1EPHX1NPC1SMN1; SMN2RAB9A
Trifluoroacetic Acid SCHEMBL4114059 0.80 PDK1 (0.39) ALDH1A1EPHX1NPC1SMN1; SMN2RAB9A
Trifluoroacetic Acid SCHEMBL27702554 0.80 PDK1 (0.43) ALDH1A1EPHX1NPC1SMN1; SMN2RAB9A
Trifluoroacetic Acid SCHEMBL16050159 0.80 PDK1 (0.39) ALDH1A1EPHX1NPC1SMN1; SMN2RAB9A
Trifluoroacetic Acid SCHEMBL28005455 0.79 PDK1 (0.43) ALDH1A1EPHX1NPC1SMN1; SMN2RAB9A
Trifluoroacetic Acid SCHEMBL2694612 0.78 KDM1A (0.38)
Acetic Acid SCHEMBL17714091 0.78 ALDH1A1 (0.63) ALDH1A1HSD17B10EPHX1NPC1SMN1; SMN2
Carbamic Acid SCHEMBL6932729 0.78 ALDH1A1 (0.63) ALDH1A1HSD17B10EPHX1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805289-B Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2024-05-28 CN claimed
CN-114805289-A Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2022-07-29 CN claimed
CN-114805289-B Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2024-05-28 CN disclosed
CN-114805289-A Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound 昆明理工大学 2022-07-29 CN disclosed
US-20120083526-A1 SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON LEK PHARMACEUTICALS D.D. (SI) 2012-04-05 US disclosed
US-20120071673-A1 SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE LEK PHARMACEUTICALS D.D. (SI) 2012-03-22 US disclosed
EP-2417117-A2 SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON LEK Pharmaceuticals d.d. (SI) 2012-02-15 EP disclosed
EP-2396309-A1 SYNTHESIS OF (S)-N-Ý2-(1,6,7,8-TETRAHYDRO-2H-INDENO-Ý5,4-B¨FURAN-8-YL)ETHYL¨PROPIONAMIDE LEK Pharmaceuticals d.d. (SI) 2011-12-21 EP disclosed
US-20110184058-A1 SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5, 4-B] FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF REMELTEON LEK PHARMACEUTICALS D.D. (SI) 2011-07-28 US disclosed
CN-102099348-A Synthesis of 6, 7-dihydro-1H-indolo [5,4-B ] furan-8 (2H) -one as an intermediate for the preparation of lamisterone LEK PHARMACEUTICALS 2011-06-15 CN disclosed
EP-2328882-A1 SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON LEK Pharmaceuticals d.d. (SI) 2011-06-08 EP disclosed
EP-2243775-A1 Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon LEK Pharmaceuticals d.d. (SI) 2010-10-27 EP disclosed
WO-2010115897-A2 SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON LEK PHARMACEUTICALS D.D. (SI) 2010-10-14 WO disclosed
WO-2010092107-A1 SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE LEK PHARMACEUTICALS D.D. (SI) 2010-08-19 WO disclosed
WO-2010007022-A1 SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON LEK PHARMACEUTICALS D.D. (SI) 2010-01-21 WO disclosed
US-20090221811-A1 PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES CHEMAGIS LTD. (IL) 2009-09-03 US disclosed
WO-2007092705-A2 PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES CHEMAGIS LTD. (IL) 2007-08-16 WO disclosed
US-20070191598-A1 Process for Preparing Gemcitabine and Associated Intermediates CHEMAGIS LTD. (IL) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083526-A1 SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON CYP2J2, CYP2E1, CYP2B6 ALDH1A1 116/4885HSD17B10 624/4885EPHX1 553/4885
US-20110184058-A1 SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5, 4-B] FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF REMELTEON CYP2B6, CYP2D6, CYP2J2 ALDH1A1 219/4885HSD17B10 378/4885EPHX1 495/4885
US-20120071673-A1 SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE CYP2B6, CYP2D6, CYP2A6 ALDH1A1 779/4885HSD17B10 2704/4885EPHX1 848/4885
US-20070191598-A1 Process for Preparing Gemcitabine and Associated Intermediates DCTD, DPYD, THPO ALDH1A1 718/4885HSD17B10 3827/4885EPHX1 97/4885
US-20090221811-A1 PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES THPO, DPYD, DCTD ALDH1A1 722/4885HSD17B10 3425/4885EPHX1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.